RxDoctor Payments DataLook up a doctor →

Victor Czerkasij, NP

Nurse Practitioner · Dalton, GANPI 1295893204

Payments from drug & device makers

$504,874in general payments, 2019–2025

Across 1,694 payments — averaging $298.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$144K
  • AbbVie$99K
  • Regeneron Healthcare Solutions, Inc.$53K
  • Sanofi$38K
  • Lilly USA, LLC$34K
  • Janssen Scientific Affairs, LLC$24K
  • plus $113K from 28 others
$11,180in research payments, 2019–2025

Across 9 payments — averaging $1242.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$11K

What the payments were for

  • Consulting fees$85,31617%
  • Speaking & faculty fees$336,14567%
  • Travel & lodging$48,65110%
  • Food & beverage$33,9167%
  • Education$8460%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$504,874 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$174,666
Medicare patients
916
Services billed
5,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab153$593,351
Dupixent PenDupilumab113$498,664
Skyrizi PenRisankizumab-Rzaa17$374,169
Humira(Cf) PenAdalimumab23$342,100
Cosentyx Unoready PenSecukinumab22$291,089
TremfyaGuselkumab15$210,713
Clobetasol Propionate91$6,599
Metronidazole72$5,360
Triamcinolone Acetonide311$3,772
Fluorouracil41$3,760
Acitretin15$3,467
Ketoconazole237$3,019
Clindamycin Phosphate31$1,082
Minoxidil119$967
Minocycline Hcl36$716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$143,506$210,71315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →